CG 428
A Legacy Healthcare cutaneous solution trialled in persistent chemotherapy-induced alopecia.
No public activity in over 18 months
- Developed by
- Legacy Healthcare
- Current phase
- Phase 2
- Indications
- Chemotherapy-induced alopecia
- Last public activity
- August 2019
- Record confidence
- Low
Tests whether it works, at what dose, in a few hundred people.
Why it matters
Hair that does not come back after chemotherapy is a distinct problem from hair lost during it, and almost nothing is in development for it. Legacy already appears in this register for a separate programme; this is the second.
Development history
- Phase 2
First Phase 2 trial on record: NCT02919735 — Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)
Legacy Healthcare SA · n=40 · October 2016
EValuation of the Impact of a TOpical Lotion on Permanent Chemotherapy Induced Hair Disorders in Cancer Survivors
Samsung Medical Center · n=32 · July 2016
A 6-month Post-interventional Follow-up Extension of VOLUME Study (VOLUME-2)
Samsung Medical Center · n=19 · January 2016
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- CG 428 cutaneous solution in chemotherapy-induced alopecia — ClinicalTrials.gov